Compartir
array:23 [ "pii" => "S0025775300715491" "issn" => "00257753" "doi" => "10.1016/S0025-7753(00)71549-1" "estado" => "S300" "fechaPublicacion" => "2000-01-01" "aid" => "71549" "copyright" => "Elsevier España, S.L.. Todos los derechos reservados" "copyrightAnyo" => "2000" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2000;115:337-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1596 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 1462 "PDF" => 128 ] ] "itemSiguiente" => array:18 [ "pii" => "S0025775300715508" "issn" => "00257753" "doi" => "10.1016/S0025-7753(00)71550-8" "estado" => "S300" "fechaPublicacion" => "2000-01-01" "aid" => "71550" "copyright" => "Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2000;115:339-40" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1830 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 1735 "PDF" => 87 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Frecuencia del déficit selectivo de IgA en el País Vasco" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "339" "paginaFinal" => "340" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Frequency of selective IgA deficiency in Basque Country (Spain)" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Ángel Pérez Vaquero, Miguel Ángel Vesga Carasa, Antonio López Urrutia" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Miguel" "apellidos" => "Ángel Pérez Vaquero" ] 1 => array:2 [ "nombre" => "Miguel" "apellidos" => "Ángel Vesga Carasa" ] 2 => array:2 [ "nombre" => "Antonio" "apellidos" => "López Urrutia" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775300715508?idApp=UINPBA00004N" "url" => "/00257753/0000011500000009/v1_201307291648/S0025775300715508/v1_201307291648/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S002577530071548X" "issn" => "00257753" "doi" => "10.1016/S0025-7753(00)71548-X" "estado" => "S300" "fechaPublicacion" => "2000-01-01" "aid" => "71548" "copyright" => "Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2000;115:332-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 15250 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 14696 "PDF" => 548 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Utilidad de la fracción libre del antígeno prostático específico en el diagnóstico diferencial entre hiperplasia prostática benigna y cáncer de próstata" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "332" "paginaFinal" => "336" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Usefulness of percentage of free prosthatic specific antigen in the differential diagnosis between benign prostatic hyperplasia and prostate cancer" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:2 [ 0 => array:2 [ "autoresLista" => "M.ª Jesús Gaspar, Ignacio Arribas, Carmen Coca" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M.ª Jesús" "apellidos" => "Gaspar" ] 1 => array:2 [ "nombre" => "Ignacio" "apellidos" => "Arribas" ] 2 => array:2 [ "nombre" => "Carmen" "apellidos" => "Coca" ] ] ] 1 => array:2 [ "autoresLista" => "José. Manuel Hontoria, Paloma Bokobo, C. Javier Angulo" "autores" => array:3 [ 0 => array:2 [ "nombre" => "José." "apellidos" => "Manuel Hontoria" ] 1 => array:2 [ "nombre" => "Paloma" "apellidos" => "Bokobo" ] 2 => array:2 [ "nombre" => "C." "apellidos" => "Javier Angulo" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S002577530071548X?idApp=UINPBA00004N" "url" => "/00257753/0000011500000009/v1_201307291648/S002577530071548X/v1_201307291648/es/main.assets" ] "es" => array:13 [ "idiomaDefecto" => true "titulo" => "Toxicidad asociada a efavirenz en personas infectadas por el VIH incluidas en el programa de acceso expandido" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "337" "paginaFinal" => "338" ] ] "autores" => array:2 [ 0 => array:4 [ "autoresLista" => "Carmen Dona, Vicenç Soriano, Pablo Barreiro, Juan González-Lahoz" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Carmen" "apellidos" => "Dona" ] 1 => array:4 [ "nombre" => "Vicenç" "apellidos" => "Soriano" "email" => array:1 [ 0 => "vsoriano@dragonet.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 2 => array:2 [ "nombre" => "Pablo" "apellidos" => "Barreiro" ] 3 => array:2 [ "nombre" => "Juan" "apellidos" => "González-Lahoz" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicios de Enfermedades Infecciosas. Hospital Carlos III. Instituto de Salud Carlos III. Madrid." ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "*" "correspondencia" => "Correspondencia: Rafael Calvo, 7, 2.° A. 20810 Madrid." ] ] ] 1 => array:3 [ "autoresLista" => "Inmaculada Jiménez-Nácher" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Inmaculada" "apellidos" => "Jiménez-Nácher" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Farmacia. Hospital Carlos III. Instituto de Salud Carlos III. Madrid." "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "1999-10-21" "fechaAceptado" => "2000-06-27" "PalabrasClave" => array:1 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec222515" "palabras" => array:4 [ 0 => "VIH Infección por VIH" 1 => "Antiretrovirales" 2 => "Efavirenz" 3 => "Toxicidad medicamentosa" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<span class="elsevierStyleSectionTitle">Fundamento</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">El efavirenz es uno de los antiretrovirales de más reciente comercialización. Su perfil de toxicidad no se conoce bien.</p> <span class="elsevierStyleSectionTitle">Pacientes y método</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se examinó la frecuencia de efectos adversos en 250 pacientes incluidos en el programa de acceso expandido de efavirenz en una institución de Madrid.</p> <span class="elsevierStyleSectionTitle">Resultados</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Se recogieron efectos adversos de grado ≥ 2 en la escala de la Organización Mundial de Salud en 33 (13,2%) pacientes. Los más frecuentes fueron los trastornos neuropsiquiátricos (8,4%), cutáneos (3,2%) y gastrointestinales (0,8%). En 17 pacientes (6,8%) tuvo que ser suspendido el efavirenz.</p> <span class="elsevierStyleSectionTitle">Conclusiones</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">La frecuencia de efectos adversos por efavirenz de grado moderadograve es relativamente baja (13,4%), sin evidencia de toxicidad cruzada (p. ej., exantema por nevirapina). Las complicaciones más frecuentes son neuropsiquiátricas y/o cutáneas, y se resuelven espontáneamente en dos semanas.</p>" ] "en" => array:1 [ "resumen" => "<span class="elsevierStyleSectionTitle">Background</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Efavirenz (EFV) is one of the latest antiretroviral compounds appeared in the market. Its toxicity profile is not well known.</p> <span class="elsevierStyleSectionTitle">Patients and methods</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">The rate of adverse events was examined in 250 subjects enrolled in the expanded access program in a single institution located in Madrid, Spain.</p> <span class="elsevierStyleSectionTitle">Results</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Adverse events grade ≥ 2 (WHO) were recorded in 33 (13.2%) persons. The most common were neuropsychiatric disorders (8.4%), cutaneous lesions (3.2%), and gastrointestinal problems (0.8%). The drug needed to be discontinued in 17 (6.8%) patients.</p> <span class="elsevierStyleSectionTitle">Conclusions</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">The rate of adverse events grade moderate-to-severe in patients receiving EFV is relatively low (13.4%), without evidence of cross-toxicity (i.e., rash by nevirapine). Neuropshychiatric and dermatological conditions are the most common, and ten to resolve spontaneously in two weeks.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Referencias Bibliográficas" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efavirenz" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Adkins" 1 => "S. Noble" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "1998" "volumen" => "56" "paginaInicial" => "1055" "paginaFinal" => "1067" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9878993" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-1 infected patients: the INCAS Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Montaner" 1 => "P. Reiss" 2 => "D. Cooper" 3 => "S. Vella" 4 => "M. Harris" 5 => "B. Conway" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "1998" "volumen" => "279" "paginaInicial" => "930" "paginaFinal" => "937" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9544767" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Staszewski" 1 => "J. Morales-Ramírez" 2 => "K. Tashima" 3 => "A. Rachlis" 4 => "D. Skiest" 5 => "J. Standford" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199912163412501" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1999" "volumen" => "341" "paginaInicial" => "1865" "paginaFinal" => "1873" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10601505" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Murphy" 1 => "C. Katlama" 2 => "V. Johnson" 3 => "A. Collier" 4 => "J. Lange" 5 => "J.M. Gatell" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "1999" "editorial" => "39<span class="elsevierStyleSup">th</span>ICAAC" "editorialLocalizacion" => "San Francisco" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reversion of metabolic abnormalities after swithching from HIV-1 protease inhibitors to nevirapine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "E. Martínez" 1 => "I. Conget" 2 => "L. Lozano" 3 => "R. Casamitjana" 4 => "J. Gatell" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "1999" "volumen" => "13" "paginaInicial" => "805" "paginaFinal" => "810" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10357379" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efavirenz in the management of HIV infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "B. Gazzard" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Clin Pract" "fecha" => "1999" "volumen" => "53" "paginaInicial" => "60" "paginaFinal" => "64" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10344069" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Saint-Marc" 1 => "M. Partisani" 2 => "I. Poizot-Martin" 3 => "F. Bruno" 4 => "O. Rouviere" 5 => "J. Lange" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "1999" "volumen" => "13" "paginaInicial" => "1659" "paginaFinal" => "1667" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10509567" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Redestribution of body fat in HIV-infected women undergoing combined antiretroviral therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Gervasoni" 1 => "A.L. Ridolfo" 2 => "G. Trifiro" 3 => "S. Santambrogio" 4 => "G. Norbiato" 5 => "M. Musicco" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "1999" "volumen" => "13" "paginaInicial" => "465" "paginaFinal" => "471" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10197374" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L. Ruiz" 1 => "J. Van Lunzen" 2 => "A. Arno" 3 => "B. Clotet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "1999" "volumen" => "13" "paginaInicial" => "1" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10207540" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Higher antiviral activity of antiretroviral regimens including protease inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C. De Mendoza" 1 => "V. Soriano" 2 => "R. Rodríguez-Rosado" 3 => "J. González Lahoz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "1999" "volumen" => "13" "paginaInicial" => "998" "paginaFinal" => "999" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10371186" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00257753/0000011500000009/v1_201307291648/S0025775300715491/v1_201307291648/es/main.assets" "Apartado" => array:4 [ "identificador" => "24087" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Original breve" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00257753/0000011500000009/v1_201307291648/S0025775300715491/v1_201307291648/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775300715491?idApp=UINPBA00004N" ]
